Benefits and risks of furosemide in acute kidney injury

Anaesthesia

Volumn 65, Issue 3, 2010, Pages 283-293

  Ho, Kwok M ^a   Power, B M ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Joondalup Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALBUMIN; AMINOGLYCOSIDE; AMPHOTERICIN; BICARBONATE; BUMETANIDE; CARBOXYLIC ACID; CEPHALOSPORIN; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FUROSEMIDE; GENTAMICIN; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; OXIPURINOL; PENICILLIN G; PHENYTOIN; PLACEBO; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; THEOPHYLLINE; TORASEMIDE; VANCOMYCIN; WARFARIN;

ACIDURIA; ACUTE KIDNEY FAILURE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTRAST INDUCED NEPHROPATHY; DISEASE SEVERITY; DIURESIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; DRUG WITHDRAWAL; FLUID BALANCE; HEMODYNAMIC PARAMETERS; HENLE LOOP; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPROTEINEMIA; HYPOVOLEMIA; KIDNEY FUNCTION; KIDNEY INJURY; METABOLIC ACIDOSIS; MORTALITY; MUCOCILIARY CLEARANCE; NEPHROTOXICITY; OTOTOXICITY; RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; URINE VOLUME; VASOCONSTRICTION;

DIURETICS; EVIDENCE-BASED MEDICINE; FUROSEMIDE; HUMANS; KIDNEY FAILURE, ACUTE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 76649105121     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2009.06228.x     Document Type: Review

References (80)

1. Uchino S, Kellum JA, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. Journal of the American Medical Association 2005; 294: 813-8.
2. Eachempati SR, Wang JC, Hydo LJ, Shou J, Barie PS. Acute renal failure in critically ill surgical patients: persistent lethality despite new modes of renal replacement therapy. Journal of Trauma 2007; 63: 987-93.
3. Frankel MC, Weinstein AM, Stenzel KH. Prognostic patterns in acute renal failure: the New York Hospital, 1981-1982. Clinical and Experimental Dialysis and Apheresis 1983; 7: 145-67.
4. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004; 8: R204-12.
5. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. Journal of American Society of Nephrology 2000; 11: 97-104.
6. Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweizerische medizinische Wochenschrift 1996; 126: 666-73.
7. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. New England Journal of Medicine 1994; 331: 1416-20.
8. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, doubleblind, placebo-controlled, randomized study. Nephrology Dialysis Transplantation 1997; 12: 2592-6.
9. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clinical Nephrology 1981; 15: 90-6.
10. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL. High-Dose Flurosemide in Acute Renal Failure Study Group. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. American Journal of Kidney Diseases 2004; 44: 402-9.
11. Cantarovich F, Fernandez JC, Locatelli A, Perez Loredo J. Frusemide in high doses in the treatment of acute renal failure. Postgraduate Medical Journal 1971; 47 (Suppl.): 13-7.
12. Karayannopoulos S. High-dose frusemide in renal failure. British Medical Journal 1974; 2: 278-9.
13. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J. Furosemide in acute oliguric renal failure. A controlled trial. Nephron 1976; 17: 51-8.
14. van der Voort PH, Boerma EC, Koopmans M, et al. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Critical Care Medicine 2009; 37: 533-8.
15. Mahesh B, Yim B, Robson D, Pillai R, Ratnatunga C, Pigott D. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a doubleblinded prospective randomised trial European Journal of Cardiothoracic Surgery 2008; 33: 370-6.
16. Robey RB, Lash JP, Arruda JA. Does furosemide have a role in the management of hypercalcemia? Annals of Internal Medicine 2009; 150: 146-7.
17. Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. British Medical Journal 2006; 333: 420.
18. Pichette V, du Souich P. Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. Journal of American Society of Nephrology 1996; 7: 345-9.
19. Brater DC. Resistance to diuretics: emphasis on a pharmacological perspective. Drugs 1981; 22: 477-94.
20. Pichette V, Geadah D, du Souich P. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. Drug Metabolism and Disposition: the biological fate of chemicals 1999; 27: 81-5.
21. Pichette V, Geadah D, du Souich P. The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. British Journal of Pharmacology 1996; 119: 885-90.
22. Tongia SK. Antagonism of frusemide diuresis by diphenylhydantoin sodium. Indian Journal of Medical Research 1981; 74: 572-4.
23. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Critical Care Medicine 2005; 33: 1681-7.
24. Nishiyama A, Majid DS, Walker M III, Miyatake A, Navar LG. Renal interstitial ATP responses to changes in arterial pressure during alterations in tubuloglomerular feedback activity. Hypertension 2001; 37: 753-9.
25. Tahara H, Kusuhara H, Endou H, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. The Journal of Pharmacology and Experimental Therapeutics 2005; 315: 337-45.
26. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clinical Pharmacology and Therapeutics 1980; 28: 182-6.
27. Sjöström PA, Kron BG, Odlind BG. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration. European Journal of Clinical Pharmacology 1993; 45: 135-9.
28. Sanjay S, Annigeri RA, Seshadri R, Rao BS, Prakash KC, Mani MK. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton) 2008; 13: 247-50.
29. Ostermann M, Alvarez G, Sharpe MD, Martin CM. Frusemide administration in critically ill patients by continuous compared to bolus therapy. Nephron in Clinical Practice 2007; 107: c70-6.
30. Castañeda-Hernández G, Vergés J, Pichette V, Héroux L, Caillé G, du Souich P. Input rate as a major determinant of furosemide pharmacodynamics: influence of fluid replacement and hypoalbuminemia. Drug Metabolism and Disposition: the biological fate of chemicals 2000; 28: 323-8.
31. Ho KM, Walters S, Faulke D, Liang J. Clinical predictors of acute renal replacement therapy in critically ill patients with acute renal impairment. Critical Care and Resuscitation 2003; 5: 97-102.
32. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney International Supplements 2005; 99: S46-51.
33. Evans RG, Gardiner BS, Smith DW, O'Connor PM. Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. American Journal of Physiology Renal Physiology 2008; 295: F1259-70.
34. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation. I. Effects of diuretics. American Journal of Physiology 1994; 267: F1059-62.
35. Heyman SN, Rosen S, Epstein FH, Spokes K, Brezis ML. Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney. Kidney International 1994; 45: 981-5.
36. Rosenberger C, Heyman SN, Rosen S, et al. Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney International 2005; 67: 531-42.
37. Gerber JG, Nies AS. Furosemide induced vasodilatation: importance of state of hydration and filtration. Kidney International 1980; 18: 454-9.
38. Janssen BJ, Struyker-Boudier HA, Smits JF. Acute arteriolar vasoconstriction following furosemide in conscious spontaneously hypertensive rats. European Journal of Pharmacology 1989; 170: 1-9.
39. Andriessen P, Struis NC, Niemarkt H, Oetomo SB, Tanke RB, Van Overmeire B. Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus. Acta Paediatrics 2009; 98: 797-803.
40. 2 production after furosemide administration. Hypertension 1988; 11: 491-4.
41. Liu KD, Glidden DV, Eisner MD, et al. The National Heart, Lung, and Blood Institute ARDS Network Clinical Trials Group. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Critical Care Medicine 2007; 35: 2755-61.
42. Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. Contributions to Nephrology 2007; 156: 39-46.
43. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clinical Journal of American Society of Nephrology 2007; 2: 356-65.
44. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Seminars in Nephrology 2000; 20: 4-19.
45. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. Refining predictive models in critically ill patients with acute renal failure. Journal of American Society of Nephrology 2002; 13: 1350-7.
46. Källskog O, Nygren K, Wolgast M. Failure of loop diuretics to improve the long term outcome of ischaemic damage in rat kidneys. Upsala Journal of Medical Sciences 2001; 106: 151-60.
47. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. New England Journal of Medicine 2006; 354: 2564-75.
48. Rosenberg AL, Dechert RE, Park PK, Bartlett RH; NIH NHLBI ARDS Network. Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal volume study cohort. Journal of Intensive Care Medicine 2009; 24: 35-46.
49. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. New England Journal of Medicine 2000; 342: 1301-8.
50. Rubenfeld GD, Cooper C, Carter G, Thompson BT, Hudson LD. Barriers to providing lung-protective ventilation to patients with acute lung injury. Critical Care Medicine 2004; 32: 1289-93.
51. Cantarovich F, Verho MT. A simple prognostic index for patients with acute renal failure requiring dialysis. French Multicentric Prospective Study on Furosemide in Acute Renal Failure Requiring Dialysis. Renal Failure 1996; 18: 585-92.
52. Rastogi S, Bayliss JM, Nascimento L, Arruda JA. Hyperkalemic renal tubular acidosis: effect of furosemide in humans and in rats. Kidney International 1985; 28: 801-7.
53. Lee CT, Chen HC, Lai LW, Yong KC, Lien YH. Effects of furosemide on renal calcium handling. American Journal of Physiology Renal Physiology 2007; 293: F1231-7.
54. Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrology Dialysis Transplantation 2005; 20: 1623-9.
55. Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. Journal of Clinical Gastroenterology 2006; 40: 342-6.
56. Santoso JT, Lucci JA III, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemotherapy and Pharmacology 2003; 52: 13-8.
57. Shimada M, Johnson RJ, May WS Jr, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrology Dialysis Transplantation 2009; 24: 2960-4.
58. Zaloga GP, Hughes SS. Oliguria in patients with normal renal function. Anesthesiology 1990; 72: 598-602.
59. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. American Journal of Physiology Renal Physiology 2003; 284: F11-21.
60. Mancini ML, Dello Strologo L, Bianchi PM, et al. Sensorineural hearing loss in patients reaching chronic renal failure in childhood. Pediatric Nephrology 1996; 10: 38-40.
61. Rybak LP. Pathophysiology of furosemide ototoxicity. Journal of Otolaryngology 1982; 11: 127-33.
62. Robertson CM, Tyebkhan JM, Peliowski A, et al. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Acta Paediatrics 2006; 95: 214-23.
63. Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. American Journal of Kidney Diseases 2008; 52: 272-84.
64. Demirkiliç U, Kuralay E, Yenicesu M, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. Journal of Cardiac Surgery 2004; 19: 17-20.
65. Zager RA. Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Laboratory Investigation; a journal of technical methods and pathology 1989; 60: 619-29.
66. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. New England Journal of Medicine 2009; 361: 62-72.
67. Zager RA, Gamelin LM. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. American Journal of Physiology 1989; 256: F446-55.
68. Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Critical Care Medicine 2009; 37: 39-47.
69. Vanek T, Snircova J, Spegar J, Straka Z, Horak J, Maly M. Increase in plasma free haemoglobin during cardiopulmonary bypass in heart valve surgery: assessment of renal dysfunction by RIFLE classification. Perfusion 2009; 24: 179-83.
70. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasocontrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Annals of Internal Medicine 1985; 103: 1-6.
71. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. Journal of the American Medical Association 2004; 291: 2328-34.
72. Ho KM, Morgan DJ. Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis. Anaesthesia and Intensive Care 2008; 36: 646-53.
73. Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. American Journal of Kidney Diseases 2009; 54: 602-9.
74. Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatric Cardiology 2006; 27: 238-42.
75. Kondo CS, Macchionne M, Nakagawa NK, et al. Effects of intravenous furosemide on mucociliary transport and rheological properties of patients under mechanical ventilation. Critical Care 2002; 6: 81-7.
76. Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part I). Clinical Pharmacokinetics 1991; 20: 66-80.
77. Lawson DH, Tilstone WJ, Gray JM, et al. Effect of furosemide on the pharmacokinetics of gentamicin in patients. Journal of Clinical Pharmacology 1982; 22: 254-8.
78. Laizure SC, Madlock L, Cyr M, Self T. Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Therapeutic Drug Monitoring 1997; 19: 361-3.
79. Luszczki JJ, Sawicka KM, Kozinska J, Borowicz KK, Czuczwar SJ. Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model. Epilepsy Research 2007; 76: 66-72.
80. Cleland JG, Gillen G, Dargie HJ. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. European Heart Journal 1988; 9: 132-41.